Leptoprol (Leuprorelin)

Leuprorelin is a synthetic GnRH analogue that initially stimulates, then desensitizes pituitary GnRH receptors. This leads to a sustained fall in luteinizing hormone and follicle‑stimulating hormone, which in turn sharply reduces testosterone or estrogen synthesis, depending on the patient’s sex.

The dose of Leptoprol is individualized by the prescribing clinician based on the specific indication, disease severity, patient age, weight, and renal or hepatic function. No universal regimen is provided; the prescriber sets the appropriate dosing schedule.

Leptoprol’s pregnancy category is unknown, and it is generally contraindicated in pregnancy because it suppresses sex hormone production essential for fetal development. Use during breastfeeding is also discouraged, as the drug may pass into milk and affect the infant.

To request Leptoprol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Leptoprol contains leuprorelin, a well‑studied GnRH agonist that provides sustained hormone suppression after an initial flare. Compared with GnRH antagonists, it may cause a brief surge in hormone levels before suppression, whereas antagonists achieve immediate blockade without flare. Choice depends on clinical context, tolerability, and physician preference.

Leptoprol should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Leptoprol is supplied as a sterile solution for subcutaneous injection. The injection is typically given by a healthcare professional in a clinical setting. The injection site is rotated to minimize local irritation, and the volume administered depends on the prescribed dose.

Serious risks include cardiovascular events such as myocardial infarction, severe allergic reactions (anaphylaxis), significant loss of bone mineral density leading to fractures, and rare cases of pituitary apoplexy. Patients should be monitored regularly for cardiovascular symptoms, bone health, and any signs of hypersensitivity.

Leptoprol is contraindicated in patients with known hypersensitivity to leuprorelin or any excipients, in women who are pregnant or may become pregnant, and in individuals with uncontrolled cardiovascular disease where hormone suppression could exacerbate risk. Caution is also advised for patients with severe osteoporosis.